REFERENCES:

1. Allen TM. (1998)' Liposomal drug formulations: Rationale for development and what we can expect for the future.Drugs. 1998;56:747–56.
2. Arunothayanun P, Bernard MS, Craig DQ, Uchegbu IF, Florence AT.(2000);The effect of processing variables on the physical characteristics of nonionic surfactant vesicles (niosomes) formed from hexadecyldiglycerol ether. Int J Pharm. 201:7–14.
3. Arunothayanun P, Turton JA, Uchegbu IF, Florence AT, Preparation and in vitro in vivo evaluation of luteinizing hormone releasing hormone (LHRH)-loaded polyhedral and .spherical tubular niosomes.Journal Of Pharmaceutical Sciences 1999;88:34-38.
4. Bertrand N, Leroux JC. (2011). "The journey of a drug carrier in the body: an anatomo-physiological perspective". Jou. of Cont. Rel. Doi: 10.1016 /j.jconrel.2011.09.098.
5. Brewer JM, Alexander J. The adjuvant activity of non-ionic surfactant vesicles (niosomes) on the BALB/c humoral response to bovine serum albumin. Immunology. 1992;75:570–5.
6. Chien, Y. W. (1980) In: Drug delivery systems: Characteristics and biomedical applications. (Juliano, R. L., ed.) pp. 11-83, New York, Oxford. Oxford University Press.
7. El Maghraby GM, Barry BW, Williams AC(2008); Liposomes and skin: from drug delivery to model membranes., Eur J Pharm Sci. 34(4-5):203-22.
8. HimanshuAnwekar*, Sitasharan Patel and A.K Singhai (2011) Liposome- as drug carriers, IntJouPha r life Sci,2(7), 945-951.
9. Hu C, Rhodes DG. Proniosomes: A Novel Drug Carrier Preparation. Int J Pharm. 1999;185:23–35.
10. Jadon PS, Gajbhiye V, Jadon RS, Gajbhiye KR, Ganesh N. Enhanced oral bioavailability of griseofulvin via niosomes. AAPS PharmSciTech. 2009;10:1186–92.
11. Jaya VaishnaviChennam*, SirishaVelchuri, BabuRaoChandu and AmulyaAla (2010), Niosomes – A Novel Drug Carrier Approach, International Journal of Research in Pharmaceutical and Biomedical Sciences, Vol. 3 (2), 722-729.

12. Jayaraman CS, Ramachandran C and Weiner N, Topical delivery of erythromycin from various formulations: an in vivo hairless mouse study. J. Pharm. Sci. 85 (10), 1996, 1082-1084.
13. K B Bini, D. Akhilesh*, P. Prabhakara, Kamath J.V (2010), Development and Characterization of Non-Ionic Surfactant Vesicles (Niosomes) for Oral delivery of Lornoxicam, Int. J. Drug Dev. & Res., 4 (3): 147-154.
14. K B Bini, D. Akhilesh*, P. Prabhakara, Kamath J.V (2010), Development and Characterization of Non-Ionic Surfactant Vesicles (Niosomes) for Oral delivery of Lornoxicam, Int. J. Drug Dev. & Res., 4 (3): 147-154.
15. K.SwaroopKumar.S.L.V.V.S.N, T. Jyothi, s. Nagendar, s.devipriya , (2008) stability of liposomes, international journal of advances in pharmaceutical sciences, vol.2 (4), 301-307.
16. KaurDiljyot, (2011)Niosomes: A New Approach to Targeted Drug Delivery, Int.J.Pharm.Phytopharmacol.Res. 2012, 2(1): 53-59.
17. **Kaur IP**, Garg A, Singla AK, Aggarwal D. **(**2004**)**Vesicular systems in ocular drug delivery: An overview. Int J Pharm.2004;269:1–14.
18. Liangfang Zhang and Steve Granick (2006) How to Stabilize Phospholipid Liposomes (Using Nanoparticles) nano let,6(4),694-698.
19. Madhav NVS* and Saini A, (2009) Niosomes: A Novel Drug Delivery System. Int. J. Res Pharm chem.,(3), 498-511.
20. Manconi M, Sinico C, Valenti D, Lai F, Fadda AM. (2006);Niosomes as carriers for tretinoin. III. A study into the in vitro cutaneous delivery of vesicle-incorporated tretinoin.Int J Pharm. 311(1-2):11-9.
21. Mohammad Riaz (1996) Liposomes Preparation Methods, Pakistan Journal of Pharmaceutical Sciences Vol.19(1), 65-77.
22. Mohammad Riaz (1996) Liposomes Preparation Methods, Pakistan Journal of Pharmaceutical Sciences Vol.19(1), 65-77.
23. Mohammad riaz, (1995), Stability and uses of liposomes, Pak. Jou pharm. Sci. Vol 8(2); pp 69-79.

24. Raj K. Keservani*1, Anil K. Sharma2, Md. Ayaz1, Rajesh K. Kesharwani3, (2010), Novel drug delivery system for the vesicular delivery of drug by the niosomes, International Journal of Research in Controlled Release, 1 (1) 1-8.
25. Raja Naresh R A, Udupa N, Anti-inflammatory activity of niosome encapsulated diclofenac sodium in arthritis rats.international journal of pharmaceutics1994; volume-26, Issue1:46-48
26. Rajesh Mujoriya, Ramesh BabuBodla, KishorDhamande, Devendrasingh , LokeshPatle (2010), Niosomal Drug Delivery System: The Magic Bullet, Journal of Applied Pharmaceutical Science 01 (09); 20-23.
27. Ranjana Sharma*, Ritu Mahatma, MeenakshiBharkatiya and AnjuGoyal, (2010), Niosomes - As Potential Drug Delivery System, Int. Jour. .Drug Res. Tech,Vol. 2 (6), 422-429.
28. Ruckmani K, Jayakar B, Ghosal S K, Nonionic surfactant vesicles (niosomes) of cytarabine hydrochloride for effective treatment of leukemias: encapsulation, storage, and in vitro release. Drug Development and Industrial Pharmacy2000; 26:217–222.
29. S Gopalakrishnan A Chenthilnathan. (2010), niosomes – a novel drug delivery device Res.Jour. Phar. Bio.Chem. Sci. Volume 3 Issue 3 1090-1095.
30. Sakthivel M, Kannan K, Manavalan R, Senthamarai R (2010) Non Ionic Surfactant Vesicles – A Review, RJPBCS Volume 3 Issue 1 604-614.
31. Saltzman, W. Mark; Torchilin, Vladimir P. (2008). "Drug delivery systems". AccessScience. McGraw-Hill Companies.
32. SaurabhBansal, Chandan Prasad Kashyap, GeetaAggarwal and S Harikumar, (2010), A comparative review on vesicular drug Delivery system and stability int. jour. Res. c 2012, 2(3) 704-713.
33. SurenderVerma, S. K. Singh, NavneetSyan, PoojaMathur, VinayValecha, (2010). Nanoparticle vesicular systems: A versatile tool for drug delivery J. Chem. Pharm. Res., 2010, 2(2): 496-50.
34. V. Pola Chandu1*, A.Arunachalam1, S.Jeganath2, K.Yamini1, K.Tharangini1, G.Chaitanya1,(2010) Niosomes: A Novel Drug Delivery System, Int. Jour. Novel Trends Pharm Scies, VOL2 (1) 25-31.
35. YadavA.V , Murthy M.S , Shete A. S* and SfurtiSakhare, (2011) Stability Aspects of Liposomes,Ind J Pharm Edu Res, Vol 45(4) 402-413.